The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Bacterial superglue enables easy development of efficient virus-like particle based vaccines
Open accessAbstract
BACKGROUND: Virus-like particles (VLPs) represent a significant advance in the development of subunit vaccines, combining high safety and efficacy. Their particulate nature and dense repetitive subunit organization makes them ideal scaffolds for display of vaccine antigens. Traditional approaches for VLP-based antigen display require labor-intensive trial-and-error optimization, and often fail to generate dense antigen display. Here we utilize the split-intein (SpyTag/SpyCatcher) conjugation system to generate stable isopeptide bound antigen-VLP complexes by simply mixing of the antigen and VLP components. RESULTS: Genetic fusion of SpyTag or SpyCatcher to the N-terminus and/or C-terminus of the Acinetobacter phage AP205 capsid protein resulted in formation of stable, nonaggregated VLPs expressing one SpyCatcher, one SpyTag or two SpyTags per capsid protein. Mixing of spy-VLPs with eleven different vaccine antigens fused to SpyCatcher or SpyTag resulted in formation of antigen-VLP complexes with coupling efficiencies (% occupancy of total VLP binding sites) ranging from 22-88 %. In mice, spy-VLP vaccines presenting the malaria proteins Pfs25 or VAR2CSA markedly increased antibody titer, affinity, longevity and functional efficacy compared to corresponding vaccines employing monomeric proteins. The spy-VLP vaccines also effectively broke B cell self-tolerance and induced potent and durable antibody responses upon vaccination with cancer or allergy-associated self-antigens (PD-L1, CTLA-4 and IL-5). CONCLUSIONS: The spy-VLP system constitutes a versatile and rapid method to develop highly immunogenic VLP-based vaccines. Our data provide proof-of-concept for the technology's ability to present complex vaccine antigens to the immune system and elicit robust functional antibody responses as well as to efficiently break B cell self-tolerance. The spy-VLP-system may serve as a generic tool for the cost-effective development of effective VLP-vaccines against both infectious- and non-communicable diseases and could facilitate rapid and unbiased screening of vaccine candidate antigens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T. R., Sowa, M. P. K., Arnot, D. E., Hviid, L., & Theander, T. G. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03570.x · Cited by 702
Self-citationStaalsoe, T., Shulman, C. E., Bulmer, J. N., Kawuondo, K., Marsh, K., & Hviid, L. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15386-x · Cited by 288
Nielsen, M. A., Pinto, V. V., Resende, M., Dahlbäck, M., Ditlev, S. B., Theander, T. G., & Salanti, A. (2009) · Infection and Immunity · doi:10.1128/iai.00159-09 · Cited by 92 · cited 2×
“Inhibition of binding assays Plasmodium falciparum (FCR3 genotype) parasites were maintained in culture as described [60].”
MethodSelf-citationStructural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA
Andersen, P., Nielsen, M. A., Resende, M., Rask, T. S., Dahlbäck, M., Theander, T., Lund, O., & Salanti, A. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.0040042 · Cited by 79
Self-citation
Cited by
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Tan, T. K., Rijal, P., Rahikainen, R., Keeble, A. H., Schimanski, L., Hussain, S., Harvey, R., Hayes, J. W. P., Edwards, J. C., McLean, R. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20654-7 · Cited by 283
Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination
Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J., & Howarth, M. (2018) · ACS Nano · doi:10.1021/acsnano.8b02805 · Cited by 281
Protein-based antigen presentation platforms for nanoparticle vaccines
Nguyen, B., & Tolia, N. H. (2021) · npj Vaccines · doi:10.1038/s41541-021-00330-7 · Cited by 271
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies
Cid, R., & Bolívar, J. (2021) · Biomolecules · doi:10.3390/biom11081072 · Cited by 176
Metadata
- Authors
- Thrane, S., Janitzek, C. M., Matondo, S., Resende, M., Gustavsson, T., de Jongh, W. A., Clemmensen, S., Roeffen, W., van de Vegte‑Bolmer, M., van Gemert, G. J., Sauerwein, R., Schiller, J. T., Nielsen, M. A., Theander, T. G., Salanti, A., & Sander, A. F.
- Venue
- Journal of Nanobiotechnology
- Published
- 2016-04-27
- Volume
- 14
- Issue
- 1
- Pages
- 30-30
- ISSN
- 1477-3155 (ISSN-L)
- OpenAlex
- W2337081411
- Cited by
- 203
- References
- 4
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bacterial superglue enables easy development of efficient virus-like particle based vaccines. https://app.cochat.ai/papers/10.1186/s12951-016-0181-1
- The paper
- Thrane, S., Janitzek, C. M., Matondo, S., Resende, M., Gustavsson, T., de Jongh, W. A., Clemmensen, S., Roeffen, W., van de Vegte‑Bolmer, M., van Gemert, G. J., Sauerwein, R., Schiller, J. T., Nielsen, M. A., Theander, T. G., Salanti, A., & Sander, A. F. (2016). Bacterial superglue enables easy development of efficient virus-like particle based vaccines. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-016-0181-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.